BOXR-1030

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameBOXR-1030
Drug Alias NameBOXR-1030
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derivedCell and gene therapy > Cell therapy > Donor > Allogeneic +[4] 
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityGlypican-3 inhibitors +[4] 
TargetsGlypican-3
Therapy Area/IndicationsLung NeoplasmsLiver NeoplasmsCarcinoma, Squamous Cell +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUnum Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSotio Biotech IncSotioUnum Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsLiver NeoplasmsCarcinoma, Squamous Cell +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A